http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 CHICAGO, Nov. 10-- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the... http://pharmalicensing.com/redirs/news_rss//public/news/view/499668/0/15/advanced-life-sciences-announces-third-quarter-2009-financial-results http://pharmalicensing.com/redirs/news_rss//public/news/view/499668/0/15/advanced-life-sciences-announces-third-quarter-2009-financial-results SOLNA, Sweden - 4 November 2009 - Aerocrine AB (OMX Nordic Exchange: AERO) today announced that Aerocrine and Panasonic Shikoku Electronics, CO., LTD (PSEC) have entered into a long-term agreement to... http://pharmalicensing.com/redirs/news_rss//public/news/view/498872/0/15/aerocrine-and-panasonic-shikoku-electronics-enter-into-asthma-partnership http://pharmalicensing.com/redirs/news_rss//public/news/view/498872/0/15/aerocrine-and-panasonic-shikoku-electronics-enter-into-asthma-partnership Mission Viejo, CA, November 4, 2009-- Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) reported that researchers from National Jewish Health and McGill University have completed a series of... http://pharmalicensing.com/redirs/news_rss//public/news/view/498873/0/15/aeolus-pharmaceuticals-aeol-10150-protects-lungs-against-chlorine-gas-exposure-in-animal-studies http://pharmalicensing.com/redirs/news_rss//public/news/view/498873/0/15/aeolus-pharmaceuticals-aeol-10150-protects-lungs-against-chlorine-gas-exposure-in-animal-studies CARY, N.C., Nov. 4 -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the... http://pharmalicensing.com/redirs/news_rss//public/news/view/498770/0/15/cornerstone-therapeutics-reports-third-quarter-2009-financial-results http://pharmalicensing.com/redirs/news_rss//public/news/view/498770/0/15/cornerstone-therapeutics-reports-third-quarter-2009-financial-results BRISBANE, Calif., November 4, 2009 -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA)... http://pharmalicensing.com/redirs/news_rss//public/news/view/498835/0/15/intermune-announces-submission-of-nda-for-pirfenidone-for-the-treatment-of-patients-with-ipf http://pharmalicensing.com/redirs/news_rss//public/news/view/498835/0/15/intermune-announces-submission-of-nda-for-pirfenidone-for-the-treatment-of-patients-with-ipf SAN DIEGO, November 3, 2009 -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange... http://pharmalicensing.com/redirs/news_rss//public/news/view/498540/0/15/medicinova-announces-initiation-of-a-phase-ib-clinical-trial-for-mn-221-in-patients-with-stable-moderate-to-severe-chronic-obstructive-pulmonary-disease http://pharmalicensing.com/redirs/news_rss//public/news/view/498540/0/15/medicinova-announces-initiation-of-a-phase-ib-clinical-trial-for-mn-221-in-patients-with-stable-moderate-to-severe-chronic-obstructive-pulmonary-disease MONTREAL, November 3, 2009 -- Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment... http://pharmalicensing.com/redirs/news_rss//public/news/view/498597/0/15/enobia-pharma-expands-clinical-program-for-enb-0040-a-bone-targeted-enzyme-replacement-therapy-for-hypophosphatasia http://pharmalicensing.com/redirs/news_rss//public/news/view/498597/0/15/enobia-pharma-expands-clinical-program-for-enb-0040-a-bone-targeted-enzyme-replacement-therapy-for-hypophosphatasia SOMERSET, N.J., Oct. 20, 2009 -- Alfacell Corporation (Pink Sheets:ACEL) today announced that it has closed a private placement with certain investors in which it raised $3.25 million in gross... http://pharmalicensing.com/redirs/news_rss//public/news/view/497924/0/15/alfacell-corporation-announces-closing-of-3-25-million-private-placement http://pharmalicensing.com/redirs/news_rss//public/news/view/497924/0/15/alfacell-corporation-announces-closing-of-3-25-million-private-placement SOUTH SAN FRANCISCO, CA (October 15, 2009) - Phase 1/2 clinical trial results with KB001, a Humaneered(TM), high-affinity antibody fragment under development by KaloBios Pharmaceuticals, Inc. in... http://pharmalicensing.com/redirs/news_rss//public/news/view/499685/0/15/kalobios-kb001-antibody-shows-encouraging-safety-and-activity-in-new-approach-to-fighting-pseudomonas-infection-in-cystic-fibrosis-patients http://pharmalicensing.com/redirs/news_rss//public/news/view/499685/0/15/kalobios-kb001-antibody-shows-encouraging-safety-and-activity-in-new-approach-to-fighting-pseudomonas-infection-in-cystic-fibrosis-patients